Optologix and enEvolv Announce License Agreement
DALLAS, TX and BOSTON, MA, February 11, 2016 – Optologix and enEvolv announced today a license agreement for the use of Optologix’s light-controlled gene expression technology, LITE switch, for enEvolv’s internal research use. Under the terms of the agreement, Optologix has granted enEvolv a nonexclusive license to the LITE switch technology to use in internal research and the engineering of custom microorganisms. enEvolv plans to use LITE switch in its Multiplex Automated Genome Engineering (MAGE) technology.
About Optologix, LLC
Optologix LLC, (Dallas and New York), a biotechnology company and UT Southwestern spinoff, is focused on developing the next generation of optogenetic tools to further expand the utility of this groundbreaking approach beyond the neuroscience area to the cell biology field. Optologix provides optogenetic solutions, in the form of custom reagents and services as well as licensing agreements, for diverse manufacturing, R&D, diagnostic and therapeutic needs.
About enEvolv, Inc.
enEvolv, Inc. (Boston) engineers microbes to produce bio-based products. They partner with companies in therapeutics, nutrition, energy and specialty chemicals to improve existing strains and develop novel ones. enEvolv’s technologies harness and accelerate evolution – enabling them to build and screen genomic designs in massive parallel – resulting in unprecedented efficiency and effectiveness in strain engineering. Additional information can be found at www.enevolv.com.